Introduction
Tumorigenesis is a complex, multistep process, and oncogenic tyrosine kinase proteins are important in development of many human cancers (Gschwind et al., 2004) . Ligand-mediated receptor tyrosine kinase (RTK) activation can regulate proliferation, survival, migration and invasiveness in non-neoplastic cells, whereas oncogenic RTK mutations can induce constitutive kinase activation, and thereby enhance proliferation and survival in cancer cells (Drevs et al., 2003; Medinger and Drevs, 2005) . Mutant RTKs are useful therapeutic targets, as shown by the clinical successes of kinase inhibitor therapies in chronic myeloproliferative disorders, metastatic breast cancer, gastrointestinal stromal tumor (GIST) and non-small cell lung cancer (Gschwind et al., 2004; Paez et al., 2004) . GISTs arise from transformed progenitor cells committed to differentiation along the interstitial cell of Cajal lineage and are the most common mesenchymal tumors of the gastrointestinal tract (Fletcher et al., 2002) . GISTs are heterogeneous histologically, including spindle cell (70%), epithelioid cell (20%) and mixed types (10%) . Most GISTs contain oncogenic gain-of-function RTK mutations, involving KIT (B85%) or PDGFRA (B5%), which are accompanied by strong expression of the protein products of these oncogenes (Hirota et al., 1998; Heinrich et al., 2003; Corless et al., 2004) . KIT oncoproteins remain crucial to the proliferation and survival of GIST cells in patients with metastatic GIST, as evidenced by the clinical successes of KIT kinase inhibition by imatinib (Gleevec) and sunitinib (Sutent), in vitro and in the clinic (Tuveson et al., 2001; Demetri et al., 2002) . Indeed, imatinib therapy has rapidly become the standard of care in patients with metastatic GIST (Blay et al., 2005) .
PKCy is a member of the novel family of protein kinase C proteins, and-unlike the conventional protein kinase C proteins-shows a narrow range of expression in human cells. PKCy expression was described initially in T and myogenic cells (Baier et al., 1993; Chang et al., 1993) , but can be expressed at even higher levels in GIST (Allander et al., 2001; Nielsen et al., 2002; Duensing et al., 2004a; Medeiros et al., 2004) . PKCy is a calcium-independent but phospholipid-dependent dual-specificity kinase, which is activated by the second messenger diacylglycerol (Teixeira et al., 2003) . PKCy biologic roles have been evaluated extensively in T cells, where PKCy regulates interleukin-2 production and CD25 expression by activating nuclear factor-kB (NFkB) and activator protein-1 (Sun et al., 2000; Bi et al., 2001) . PKCy:NFkB interactions can be bidirectional, as in the case of T-cell receptor (TCR)-induced NFkB activation, regulated by 3-phosphoinositidedependent kinase 1, which can activate PKCy, resulting in PKCy recruitment to lipid rafts (Lee et al., 2005) . TCR pathways also regulate PKCy tyrosine phosphorylation, which is mediated by SRC family protein tyrosine kinases such as LCK (Liu et al., 2000) . In addition, PKCy can regulate gene expression, functioning as a positive modulator of retinoid X receptorresponsive element (RXRE)-dependent transcription during T-cell activation (Ishaq et al., 2002) . PKCy also has biologic roles outside T-cell activation, including phosphorylation-mediated regulation of cytoskeletal assembly and barrier permeability in intestinal monolayers (Banan et al., 2004 (Banan et al., , 2005 . Equally compelling roles for PKCy are likely in GIST, given the strong expression and activation of PKCy in these tumors Duensing et al., 2004a; Motegi et al., 2005) . Although preliminary studies were consistent with a PKCy prooncogenic role in GIST (Duensing et al., 2004a) , conventional PKCs can inhibit ligandmediated KIT activation, in a negative feedback loop, by phosphorylating KIT on S741 and S746 (Blume-Jensen et al., 1993 , 1994 , 1995 . Therefore, it is unclear whether PKCy has positive or negative regulatory roles, or both, in KIT-mutant GISTs.
Although KIT inhibition by imatinib represents a major therapeutic advance for patients with inoperable GIST, most patients eventually experience clinical progression due to the emergence and outgrowth of multiple imatinib-resistant GIST clones (Heinrich et al., 2006) . These imatinib-resistant clones often contain secondary mutations in the KIT kinase domain (Heinrich et al., 2006) . Novel multi-targeted kinase inhibitors such as sunitinib show activity in some patients with imatinib-resistant GIST, but are not uniformly effective, and it is therefore important to identify alternative signaling targets for therapies in GIST. PKCy is an attractive therapeutic target in GIST because it is expressed in few normal cell types. Therefore, highly selective PKCy inhibitor therapies might be accompanied by minimal toxicities in GIST patients.
In the present study, PKCy and KIT protein expression were stably silenced by lentiviral PKCy and KIT short-hairpin RNA (shRNA) constructs in a KIT þ /PKCy þ imatinib-sensitive GIST cell line (GIST882), two KIT þ /PKCy þ imatinib-resistant GIST cell lines (GIST48 and GIST430) and a control KIT þ /PKCyÀ Ewing's sarcoma cell line (EWS502). Our findings show that PKCy regulates KIT expression, cell proliferation and cell survival in GISTs, suggesting that PKCy warrants evaluation as a therapeutic target in GISTs, including those with resistance to KIT kinase inhibitors such as imatinib.
Results
PKCy is expressed and strongly phosphorylated in KIT þ GIST cell lines PKCy expression and phosphorylation were evaluated in three GIST cell lines (GIST882, GIST48 and GIST430) that express KIT oncoproteins strongly, and are therefore referred to as 'KIT positive', and in two GIST cell lines (GIST62 and GIST522) that lack KIT expression, both of which were established from KITpositive GISTs, and contain genomic KIT mutations. (Figure 1 ). PKCy expression-and phosphorylation at T538 and S676, which are required for PKCy activation-were comparable, or greater, in the KIT-positive GIST lines than in Jurkat T-cell leukemia, which has previously provided a benchmark for high levels of PKCy expression (Figure 1 ). By contrast, the two KITnegative GIST lines showed little or no demonstrable PKCy expression, and PKCy S676 phosphorylation was nearly undetectable (Figure 1 ). In general, PKCy phosphorylation in the various GIST cell lines paralleled the expression of total PKCy (Figure 1 ).
PKCy regulates KIT oncoprotein expression
To evaluate PKCy roles in imatinib-sensitive and imatinib -resistant GISTs, PKCy gene expression was stably silenced by lentivirus-mediated shRNA in GIST882, GIST48 and GIST430, and immunoblotting studies were then performed at 96 h post-infection. KIT gene silencing, also using lentiviral shRNA constructs, was evaluated in parallel studies (Figure 2a ; expression quantitations provided in Supplementary Figure 1) . The shRNA transductions resulted in greater than 60% inhibition of their intended targets. PKCy and KIT phosphorylation were also inhibited, commensurate with the reductions in total protein expression, after the shRNA interventions (Figure 2a ). KIT oncoprotein expression and phosphorylation, evaluated 96 h after PKCy shRNA infection, were substantially inhibited in the GIST48 and GIST430 imatinib-resistant GIST lines, but not in GIST882 (Figure 2a) . However, KIT shRNA knockdown did not inhibit PKCy expression in any of the GIST lines. All lentiviral experimental results were corroborated by at least two separate infections of the various GIST cell lines, and using at least one additional KIT and PKCy shRNA sequence (data not shown).
To confirm that the PKCy shRNA construct was specific for its intended target, and not binding directly to KIT mRNA, control transductions were performed in the KIT þ /PKCyÀ Ewing's sarcoma cell line, EWS502. EWS502 cells express wild-type KIT protein, but do not express PKCy (Figure 2b ). EWS502 KIT expression was inhibited at 96 h after infection with KIT lentiviral shRNA, but was unaffected after infection with lentiviral PKCy shRNA (Figure 2b ). Similarly, reduction in KIT expression was seen in EWS502 cells stably expressing KIT shRNA, but not in EWS502 cells stably expressing PKCy shRNA, after 10 and 20 days of selection with 2.5 mg/ml puromycin (Figure 2b ).
Effects of PKCy and KIT shRNA knockdown on GIST signaling pathways Alterations in proliferation and survival signaling pathways were determined by immunoblotting in the GIST882, GIST48 and GIST430 cell lines after shRNA-mediated inhibition of KIT and PKCy expression ( Figure 2c ; expression quantitations provided in Supplementary Figure 2 ). These studies evaluated phosphorylation of AKT and mitogen-activated protein kinase (MAPK), among other signaling intermediates that have been shown to be KIT dependent in GISTs Duensing et al., 2004b; Bauer et al., 2007) . Evaluations at 4 days after lentiviral shRNA infection showed that KIT silencing resulted in dramatic inactivation of AKT and S6 in the imatinib-resistant GIST48 and GIST430 cells, whereas MAPK was inactivated partially only in GIST430 (Figure 2c ). PKCy knockdown resulted in at least 50% MAPK inactivation in both GIST48 and GIST430 cells, but not in GIST882 (Figure 2c ). Likewise, PKCy knockdown partially inactivated AKT, S6 and STAT1 in GIST48 and GIST430, but not in GIST882 (Figure 2c ). Evaluations, performed in puromycin-selected GIST882 cells with stable KIT and PKCy shRNA expression, at 10 and 20 days after lentiviral infection, confirmed that AKT, but not MAPK, was inactivated after KIT silencing (Figure 3a ; expression quantitations provided in Supplementary Figure 3 ). PKCy knockdown, after 10 days and particularly after 20 days of antibiotic selection, resulted in substantial inactivation of AKT, and marked reduction in expression of total and phosphorylated KIT (Figure 3a) . Notably, these studies also reveal that substantial PDGFRA expression is substantially repressed after PKCy knockdown, but is unaffected after KIT knockdown (Supplementary Figure 3) .
Effects of PKCy and KIT shRNA knockdown on GIST proliferation KIT shRNA knockdown inhibited expression of the cyclin A and proliferating cell nuclear antigen (PCNA) proliferation markers in the imatinib-resistant GIST48 and GIST430 cell lines (Figure 2c ). PKCy shRNA knockdown also inhibited cyclin A expression in GIST48 and GIST430, and inhibited PCNA expression in GIST48 ( Figure 2c ). Cyclin A and PCNA expression were unaffected by PKCy shRNA knockdown in GIST882 at 96 h (Figure 2c ), and were not substantially downregulated in these cells after 10 and 20 day puromycin selections for stable expression of KIT and PKCy shRNAs ( Figure 3a) . However, GIST882 cell growth was reduced dramatically, when evaluated after 10 and 20 days of KIT and PKCy shRNA expression ( Figure 3b ). Cellular proliferation was evaluated by an ATP-based cell viability assay (CellTiter-Glo) in GIST882, GIST48 and GIST430 after transduction with KIT or PKCy shRNAs. Antiproliferative effects were greater in GIST882 and GIST48 cells after treatment with PKCy shRNA than after treatment with KIT shRNA. Antiproliferative effects in GIST430 cells were comparable after treatment with PKCy and KIT shRNAs (Figures 2c and 4a). All proliferation studies were corroborated by at least two independent shRNA transductions.
Proliferation-related consequences of KIT and PKCy knockdown were also determined by assessing immunoblot expression of p53 and the p21 and p27 cyclindependent kinase (CDK) inhibitors (Figure 2c ). GIST48 and GIST430 cells demonstrated upregulation of p53, p21 and p27 expression after PKCy knockdown, but not after KIT knockdown. Likewise, p27 expression was upregulated in GIST882 cells after PKCy knockdown, whereas p21 and p53 were not demonstrably expressed in these cells (Figure 2c ).
Apoptosis and cell-cycle analysis after PKCy and KIT gene knockdown Apoptosis was evaluated by assaying functional caspase 3/7 activation in GIST882 and GIST48 after transduction with KIT or PKCy shRNAs. Apoptosis was more strongly induced in these GIST cells after treatment with PKCy shRNA, compared to treatment with KIT shRNA (Figure 4b ). Cell-cycle analysis in GIST48 showed a G 1 block after KIT and PKCy silencing with an increase in the G 1/0 peak from 83.2% after empty vector transduction to 89.9 and 95.2% after transduction with KIT and PKCy shRNAs, respectively (Figure 4c ). This was accompanied by a decrease in the S-phase population from 9% with the empty vector control to 5.6 and 2.5% with KIT and PKCy shRNAs, respectively (Figure 4c ). In addition, the pre-G 1 nuclear fragmentation peak increased from 2% with empty vector control to 7 and 17% with KIT and PKCy shRNAs, respectively (Figure 4c) . Cell-cycle analysis in GIST882 showed a G 1 block after KIT silencing with an increase in the G 1/0 peak from 67.9% after empty vector transduction to 72.2% after transduction with KIT shRNA (Figure 4c) . The pre-G 1 nuclear fragmentation peak in GIST882 increased from 1% with empty vector control to 1.4 and 6.1% with KIT and PKCy shRNAs, respectively (Figure 4c ).
Discussion
Most GISTs contain oncogenic gain-of-function mutations in the KIT or PDGFRA RTK proteins. These mutations can be early-and even initiating-transforming events . Therefore, KIT/ PDGFRA inhibition by small-molecule kinase inhibitors such as imatinib mesylate or sunitinib malate has become the mainstay of treatment in patients with inoperable GIST. At the same time, studies of human GIST cell lines and transgenic mouse models have enabled substantial advances in understanding the central roles of KIT/PDGFRA signaling pathways in GIST cell proliferation and survival (Demetri et al., 2002; Heinrich et al., 2003; Duensing et al., 2004b; Corless et al., 2005; Rossi et al., 2006; Bauer et al., 2007; Zhu et al., 2007) .
Various studies have shown that PKCy is expressed strongly in GISTs, but not in other sarcoma histotypes Duensing et al., 2004a; Motegi et al., 2005) . These studies established PKCy as a diagnostic marker of GIST, but did not illuminate biological functions of PKCy. In the present work, we find strong PKCy expression in each of three KIT-positive GIST cell lines, whereas PKCy expression was weak-toundetectable in two KIT-negative GIST lines (Figure 1 ). These observations suggest that loss of PKCy expression could be responsible for inhibition of KIT expression in the KIT-negative GIST lines, both of which were established from KIT-positive GISTs, and contain genomic KIT mutations. By contrast, we have reported that PKCy is expressed in untreated KIT-negative GISTs that lack KIT mutations but often contain oncogenic PDGFRA mutations as an alternate RTK activation mechanism. Although PKCy is therefore not the sole determinant of KIT expression in GISTs, our data support a key PKCy role in enabling KIT oncogenic function in GISTs. It is also possible that KIT oncogenic signaling contributes to PKCy activation in GISTs. KIT activation is known to result in binding and activation of phosphatidylinositol-3-kinase (PI3-K) and phospholipase C-g, which regulate, respectively, membrane translocation of PKCy and synthesis of the PKCy cofactor diacylglycerol (Villalba et al., 2002; Altman and Villalba, 2003) . Further, we have shown that KIT oncoproteins complex with and tyrosine phosphorylate PKCy in GISTs, and might thereby directly activate PKCy (Zhu et al., 2007) . These observations suggest that KIT and PKCy participate in a positive feedback loop in GIST.
PKCy-mediated regulation of KIT oncoprotein expression was demonstrated in each of three KIT-positive GIST cell lines, including the imatinib-sensitive line, GIST882, and the imatinib-resistant lines, GIST48 and GIST430. However, KIT oncoprotein expression was inhibited within 4 days of PKCy shRNA transduction in GIST48 and GIST430, whereas similar effects were seen only at 10-20 days after PKCy shRNA transduction in GIST882 (Figures 2a and 3a) . One explanation for these observations is that the KIT oncoprotein in GIST882 (K642E mutant) might be more stable after PKCy knockdown compared to the hyperactivated (Bauer et al., 2007) double-mutant KIT oncoproteins in GIST48 and GIST430. Alternately, other biological variables in these unique GIST models might account for the different times of onset for KIT oncoprotein inhibition, after PKCy knockdown. The specificity of these findings was substantiated in an Ewing's sarcoma cell line (EWS502) that expresses KIT but not PKCy, and in which PKCy shRNA infection had no impact on KIT expression (Figure 2b ). These studies confirm that perturbations of KIT expression after PKCy shRNA infection in GIST lines were indeed mediated by the observed PKCy silencing in those lines. Our preliminary studies (data not shown) suggest that PKCy modulation of KIT expression in GIST involves regulation of KIT transcription. However, further studies are needed to determine whether KIT expression is regulated by PKCy biochemical activation or by PKCy scaffolding functions, but-either way-our findings show that Figure 4 (a) Cell viability was evaluated in KIT-positive GIST882 (black bars), GIST48 (gray bars) and GIST430 (white bars) cell lines, at days 8 and 12 after infection with lentiviral KIT and protein kinase C-y (PKCy) short-hairpin RNAs (shRNAs). Viability was analysed using Cell-titer Glo ATP-based luminescence assay. The data were normalized to the empty lentivirus control infections, and represent the mean values (±s.d.) from quadruplicate cultures. (b) Apoptosis was evaluated in GIST882 (black bars) and GIST48 (gray bars) cell lines, at day 4 after infection with lentiviral KIT and PKCy shRNAs. Caspase 3/7 activity was measured using a Caspase-Glo luminescence assay. The data were normalized to the empty lentivirus control infections, and represent the mean values ( ± s.d.) from quadruplicate cultures. (c) Cell-cycle analyses were performed in GIST882 and GIST48 cells at 8 and 4 days after infection by lentiviral KIT or PKCy shRNA constructs, respectively. Apoptotic response was greater, in both cell lines, after treatment with PKCy shRNA than after treatment with KIT shRNA.
KIT and PKCy have highly integrated biologic functions in GIST. In addition, preliminary studies suggest that PDGFRA-an alternate oncoprotein in GIST-is also repressed after PKCy knockdown (Supplementary Figure 3) . These findings highlight that PKCy pathway therapeutic inhibition warrants clinical evaluation as a novel strategy to downregulate KIT and PDGFRA oncoproteins, including those with imatinib-resistance mutations. PKCy targeting might also be useful therapeutically in pediatric GISTs which coexpress KIT and PKCy (Janeway et al., 2007) , and respond poorly to imatinib (K Janeway, personal communication). Further studies are needed to determine whether PKCy inactivation by small-molecule kinase inhibitiors can reproduce the spectrum of findings, demonstrated here, that result from downregulation of PKCy expression in GIST.
It is particularly intriguing that PKCy regulates KIT expression in GIST, given that PKCy and KIT have restricted ranges of expression in human cells, and are both coexpressed at unusually high levels in interstitial cells of Cajal, which are non-neoplastic counterparts of GIST (Southwell, 2003) . Although the mechanisms by which PKCy regulates KIT gene expression remain to be determined, there is precedent-in T cells-for PKCy modulation of transcriptional regulators. Namely, PKCy regulates RXRs in T cells, and the RXRs are key nuclear transcription factors that homodimerize or heterodimerize with other steroid and retinoid receptor family transcription factors (Rastinejad, 2001 ). T-cell activation signals regulate expression and transactivation of RXRa, and PKCy participates in these signaling pathways through interactions with calcineurin, resulting in increased RXRE-dependent transcription (Ishaq et al., 2002) . Further, catalytically inactive PKCy does not attenuate RXRE-dependent transcription in the T-cell models, and PKCy cooperates with calcineurin to induce Fas ligand expression during activation-induced T-cell death (Villalba et al., 1999) .
Previous studies of the GIST882 line showed parallel inactivation of KIT, AKT and MAPK, after treatment with imatinib (Duensing et al., 2004b) , suggesting that AKT and MAPK were KIT dependent in GISTs. However, our present studies, based on KIT knockdown by shRNA, while confirming that AKT is KITdependent, show that MAPK can be KIT independent, in both imatinib-sensitive and -resistant GIST lines (Figures 2c and 3a) . These findings suggest that imatinib-dependent MAPK inhibition, in GIST, might depend in part on inactivation of an alternative imatinib target, other than KIT. And these findings are consistent with those reported in EGFR-mutant lung carcinomas and in GISTs, which emphasize that the PI3-K/AKT survival pathway has a crucial role in oncogenic signaling from mutant tyrosine kinase proteins (Sordella et al., 2004; Tarn et al., 2006) . However, substantial MAPK inactivation resulted from PKCy knockdown in the imatinib-resistant GIST48 and GIST430 lines (Figure 2c) , and therefore PKCy inhibition can inactivate both PI3-K/AKT survival pathways and MAPK-dependent proliferation pathways in GISTs. This might explain why PKCy knockdown had more impact than KIT knockdown on inhibition of cyclin A expression, and on cell-cycle arrest and apoptosis in imatinibresistant GIST48 cells (Figures 2c, 4b and c) . In addition, the cellular responses seen after PKCy knockdown in GIST likely depend on dysregulation of pathways beyond those evaluated in the present study. For example, PKCy mediates activation of the NFkB transcription factor during T-cell activation (Sun et al., 2000; Wang et al., 2004) , and this PKCy function is performed through interactions with AKT (Bauer et al., 2001) . Therefore, it will be worthwhile in future studies to determine whether NFkB is a PKCy effector in GIST.
The protein kinase C family has crucial regulatory roles in cell growth and cell-cycle progression (Frey et al., 1997; Ashton et al., 1999; Jiang et al., 2002; Deeds et al., 2003; Cerda et al., 2006) . Various studies have shown that PKC suppression generally inhibits cell-cycle progression, whereas PKC activation stimulates cellcycle progression (Frey et al., 1997; Deeds et al., 2003; Cerda et al., 2006) . Therefore, we evaluated cell-cycle checkpoints after PKCy silencing in our GIST models (Figure 2c ). PKCy shRNA knockdown resulted in overexpression of the CDK inhibitors p27 and p21, and the p53 cell-cycle checkpoint protein, all of which have tumor suppressor functions in human cancer. These observations suggest that PKCy regulates cellcycle checkpoint pathways in GIST, and there is precedent for such cell-cycle control mechanisms in T cells (Deeds et al., 2003) .
Lentivirus-mediated KIT shRNA knockdown resulted in profound antiproliferative and proapoptotic effects in both imatinib-sensitive and -resistant GIST cell lines, and was associated with PI3-K/AKT signaling pathway inhibition. These findings show that KIT activation continues to serve a crucial oncogenic role in some GISTs that develop clinical resistance to imatinib (Heinrich et al., 2006) . Notably, individual patients can demonstrate heterogeneous imatinib-resistant mechanisms, for example having different KIT secondary imatinib-resistant mutations in separate clinically progressing GIST metastases (Debiec-Rychter et al., 2005; Heinrich et al., 2006) . This resistance heterogeneity, with multiple different kinase-resistant mutations in the same patient, poses a challenge to salvage therapy with alternate KIT kinase inhibitors. Specifically, it is unlikely that a given KIT kinase inhibitor will effectively inhibit the myriad different KIT structural oncoprotein variants that can be encountered in a given patient, at time of clinical progression on imatinib therapy. Therefore, the mechanism revealed in this report, whereby PKCy knockdown inhibits KIT expression, is of substantial clinical relevance, suggesting that therapeutic PKCy inhibition might repress expression of imatinib-resistant KIT oncoproteins, irrespective of whatever KIT kinase domain mutations are responsible for the imatinib resistance. The concept of PKCy therapeutic inhibition is all the more appealing in that PKCy RNAi knockdown was associated with more apoptosis than seen after KIT RNAi knockdown. Most patients with metastatic GIST benefit from imatinib therapy, having major responses, but nonetheless do not have complete responses. The residual GIST in these treated patients is generally quiescent metabolically, as evidenced by persistent negative PET scans, and cell proliferation arrest. Nonetheless, a subset of the cells survive, and can eventually progress due to imatinib-resistant mutations, suggesting that GIST survival pathways are not fully inhibited by imatinib. The observations reported here suggest that a PKCy inhibitor might lead to increased GIST apoptosis and thereby maximize the clinical response. In summary, our findings indicate that PKCy can not only serve as a diagnostic marker in GIST, but perhaps also as a novel therapeutic target of relevance in patients with both imatinib-sensitive and -resistant GIST.
Materials and methods

Antibodies and reagents
Polyclonal antibodies to KIT were from Dako (Carpinteria, CA, USA). Polyclonal antibodies to PKCy and S6 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Polyclonal antibodies to AKT, and all phospho-antibodies except phospho-KIT and phospho-STAT1 (Zymed Laboratories, South San Francisco, CA, USA), were from Cell Signaling Technologies (Danvers, MA, USA). Polyclonal antibodies to MAPK were from Zymed. Polyclonal antibodies to PI3-K p85 were from Upstate Biotechnology (Lake Placid, NY, USA). Monoclonal mouse antibodies were to cyclin A (Novocastra, Newcastle upon Tyne, UK), PCNA and p53 (Santa Cruz Biotechnology), STAT1 and p21
Cip1/WAF1 (Zymed Laboratories), p27 Kip1 (BD Transduction Laboratories, San Jose, CA, USA) and actin (Sigma-Aldrich, St Louis, MO, USA). Lipofectamine and plus reagent were from Invitrogen (Carlsbad, CA, USA). Puromycin and polybrene were from Sigma (St Louis, MO, USA).
Cell lines
GIST882 is a human cell line established from an untreated GIST with a primary imatinib-sensitive mutation in KIT exon 13 (K642E; Lux et al., 2000) . GIST48 and GIST430 are human cell lines established from GISTs progressing on imatinib therapy. GIST48 has a homozygous KIT exon 11 mutation (V560D) and a heterozygous KIT exon 17 mutation (D820A). GIST430 has heterozygous mutations in KIT exon 11 (in-frame deletion) and KIT exon 13 (V654A). GIST62 was established from an untreated GIST. This cell line, like the primary tumor from which it was established, has a heterozygous KIT exon 11 in-frame deletion mutation (resulting in MYEVQWK552-558T), but has essentially undetectable KIT and PKCy expression. GIST522 was established from a GIST progressing on imatinib therapy, and has a heterozygous KIT exon 11 inframe deletion mutation (resulting in delEVQWK554-558) but, like GIST62, has essentially undetectable KIT and PKCy expression. GIST62 and GIST522 are highly imatinib resistant (data not shown), and these cell lines serve as negative controls for interventions directed to KIT or PKCy, in a GIST cell context. EWS502 is an Ewing's tumor cell line expressing wildtype KIT. 293T cells were used to prepare lentiviral constructs.
PKCy and KIT shRNA lentiviral constructs and preparations The pLKO.1puro (7 kb) lentivirus construct contains a U6 promoter and HIV-1 RNA packaging signal with puromycinand ampicillin-resistant elements cloned 0 . Lentivirus preparations were produced by co-transfecting pLKO.1puro empty vector with PKCy or KIT shRNA, and helper virus packaging plasmids pCMVDR8.91 and pMD.G (at a 10:10:1 ratio) into 293T cells. Transfections were carried out using lipofectamine and PLUS reagent. Lentiviruses were harvested at 24, 36, 48 and 60 h post-transfection. Viral titers were determined according to a protocol from Invitrogen, in GIST882 cells. Viral preparations were then stored at À80 1C. Two well-validated shRNAs were used each for KIT and PKCy knockdown, and these shRNAs were those-screened from a panel of X KIT shRNAs and Y PKCy shRNAs-that accomplished the most efficient knockdowns of their intended targets.
Cell culture and virus infection GIST882 and EWS502 were maintained in RPMI 1640 with 15% fetal bovine serum (FBS) containing penicillin/streptomycin and L-glutamine. GIST48 and GIST430 were maintained in F10 containing 15% FBS, penicillin/streptomycin, L-glutamine, amphotericin, Mitotracker þ and bovine pituitary extract. GIST and EWS502 cells were seeded in six-well plates. Infections were carried out in the presence of 8 mg/ml of polybrene. Cells were lysed for western blot analysis at 96 h post-infection or harvested for cell-cycle analysis. Following transduction, GIST882 cells were selected for stable expression of the shRNAs using 2.5 mg/ml puromycin. Cell culture images were obtained using Spot software (version 3.5.9 for MacOS) and a Nikon Eclipse TE2000-5 microscope.
Western blotting Whole-cell lysates were prepared in lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 8.0, 100 mM sodium fluoride, 30 mM sodium pyrophosphate, 2 mM sodium molybdate, 5 mM EDTA, 2 mM sodium orthovanadate) containing protease inhibitors (10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride). Protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad Laboratories Hercules, CA, USA). Electrophoresis and western blotting were performed as described previously (Rubin et al., 2001) . Detection was by chemiluminescence (ECL, Amersham Pharmacia Biotechnology), captured using a FUJI LAS1000-plus chemiluminescence imaging system.
Cell viability and apoptosis analyses GIST882, GIST48 and GIST430 cells were plated at 5000 cells per well in 96-well flat-bottom plates from Falcon (Lincoln, NJ, USA) and cultured in RPMI 1640 or F10 for 2 days before transduction with lentiviral empty vector, PKCy shRNA or KIT shRNA. Proliferation and apoptosis studies were performed after 4, 8 and 12 days using the CellTiter-Glo luminescent assay and the Caspase-Glo 3/7 assay kit from Promega (Madison, WI, USA), and were quantitated using a Veritas Microplate Luminometer from Turner Biosystems (Sunnyvale, CA, USA). All assays were performed in quadruplicate wells, and were averaged from two independent transductions in each cell line.
Cell-cycle analysis GIST882 and GIST48 cells in six-well plates were trypsinized, centrifuged and washed once with Hank's balanced salt solution at room temperature after infection with lentivirus for 8 and 4 days, respectively. For nuclear staining, a 46-diamidino-2-phenyl indole-containing solution (nuclear isolation and staining solution; NPE Systems, Pembroke Pines, FL, USA) was added to the cells and the cell suspension was immediately analysed in a flow cytometer (NPE Quanta; NPE Systems). Data analysis was performed using Modfit LT software 3.1 (Verity Software House, Topsham, ME, USA).
